Cas no 6055-19-2 (Cyclophosphamide hydrate)

Cyclophosphamide hydrate is a nitrogen mustard alkylating agent widely used in chemotherapy and immunosuppressive therapy. As a prodrug, it is metabolized in the liver to active phosphoramide mustard, which crosslinks DNA, inhibiting cell proliferation. Its key advantages include broad-spectrum antitumor activity against hematologic malignancies (e.g., lymphomas, leukemias) and solid tumors, as well as utility in conditioning regimens for bone marrow transplantation. The hydrate form offers improved stability and solubility compared to anhydrous formulations. Its immunosuppressive properties also make it valuable in treating autoimmune disorders. As a cytotoxic agent, it requires careful dosage control and monitoring for hematologic toxicity. Proper handling is essential due to its hazardous nature.

Cyclophosphamide hydrate structure

Product Name:Cyclophosphamide hydrate

CAS No:6055-19-2

MF:C₇H₁₇Cl₂N₂O₃P

MW:279.101240873337

MDL:MFCD00149395

CID:46372

PubChem ID:24278292

Update Time:2026-05-13

Cyclophosphamide hydrate Chemical and Physical Properties

Names and Identifiers

- 2-(Bis(2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide hydrate
- N,N-Bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester amide monohydrate
- N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide monohydrate
- Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester monohydrate
- Cyclophosphamide monohydrate
- 2-[BIS(2-CHLOROETHYL)AMINO]TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE
- Cyclophosphamide
- Cyclophosphamide (hydrate)
- Cyclophosphamide monohydrate, Comet assay grade
- N,N-bis(2-chloroethyl)-2-oxo-1,3,2λ<sup>5</sup>-oxazaphosphinan-2-amine,hydrate
- Cytoxan
- 2-[Bis(2-chloroethyl)amino]tetrahydro-1,3,2-oxazaphosphorin-2-oxide Monohydrate
- Bis(2-chloroethyl)phosphoramide
- Cyclophosphamide monolydrate
- Cyclophosphamide hydrate
- Endoxon
- Endoxan monohydrate
- Ciclophosphamide hydrat
- Cytoxan hydrate
- Endoxan A
- Cyclophosphamide (hydrated)
- MLS001306483
- 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridine monohydrate
- Revimmune
- 2-(Di(2-chloroethyl)amino)-1-o
- HMS1920C04
- CCRIS 7469
- CYCLOPHOSPHAMIDE [MI]
- FT-0624277
- NCGC00254543-01
- CAS-6055-19-2
- 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide, monohydrate, (+-)
- CHEMBL1200796
- BP-12392
- 2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide monohydrate
- PWOQRKCAHTVFLB-UHFFFAOYSA-N
- Cytoxan (TN)
- N,N-Di(2-chloroethyl)amino-N,O-propylene phosphoric acid ester diamide monohydrate
- NCGC00180900-01
- 2-(Di(2-chloroethyl)amino)-1-oxa-3-aza-2-phosphacyclohexane-2-oxide monohydrate
- Cyclophosphamide,(S)
- Tox21_110100_1
- SPECTRUM1500213
- BCP9000569
- CYCLOPHOSPHAMIDE MONOHYDRATE [WHO-DD]
- Tox21_300529
- B-518
- N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine;hydrate
- Cyclophosphamide monohydrate, bulk package
- D00287
- N,N-Bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate
- HMS3259P15
- AKOS009144593
- CYCLOPHOSPHAMIDE [VANDF]
- CYCLOPHOSPHAMIDE [WHO-IP]
- NCGC00091741-01
- HMS2091I12
- CYCLOPHOSPHAMIDE [USP MONOGRAPH]
- HMS3370O11
- N,N-Bis(beta-cloraethyl) N'-O-propylenphosphorildiamid monohydratum
- Cyclophosphamide hydrate (JP17)
- SR-01000075737-4
- Cyclophosphamide monohydrate, analytical standard
- NCGC00259054-01
- N,N-Bis(beta-cloraethyl) N'-O-propylenphosphorildiamid monohydratum [Romanian]
- (+-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
- NCGC00094636-03
- 2-[bis(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one hydrate
- s2057
- Tox21_201503
- NCGC00091741-04
- CS-5005
- DTXCID604888
- CYCLOPHOSPHAMIDE HYDRATE [JAN]
- MFCD00149395
- BCP22663
- N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide hydrate
- CYCLOPHOSPHAMIDE [IARC]
- CYCLOPHOSPHAMIDE [ORANGE BOOK]
- Cycloblastin
- Q27106287
- 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide, monohydrate
- Cyclophosphamide [USP:INN:BAN:JAN]
- SCHEMBL6071
- CYCLOPHOSPHAMIDE [USP-RS]
- (+/-)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE MONOHYDRATE
- N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxaphosphorin-2-amine, 2-oxide monohydrate
- NCGC00015209-11
- HMS500M08
- 6055-19-2 (hydrate)
- Cytoxan (Lyophilized)
- C06933
- CYCLOPHOSPHAMIDUM [WHO-IP LATIN]
- Cyclic N',O-propylene ester of N,N-bis(2-chloroethyl)phosphorodiamidic acid monohydrate
- BCP0726000113
- NSC-756711
- NCGC00094636-02
- CYCLOPHOSPHAMIDE [EP MONOGRAPH]
- CHEBI:4026
- Tox21_110100
- SMR000718805
- UNII-8N3DW7272P
- AS-13677
- Cyclophosphamide, United States Pharmacopeia (USP) Reference Standard
- EN300-52512
- Cyclophosphamide, Pharmaceutical Secondary Standard; Certified Reference Material
- 2-(Bis(2-chloroethyl)amino)-1-oxa-3-aza-2-phosphocyclohexane 2-oxide monohydrate
- AC-1741
- N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide--water (1/1)
- Neosar
- HY-17420A
- SW199628-3
- NCGC00015209-05
- NS00078376
- (Bis(chloro-2-ethyl)amino)-2-tetrahydro-3,4,5,6-oxazaphosphorine-1,3,2-oxide-2 monohydrate
- NC00662
- Neosar (TN)
- NCGC00094636-01
- 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
- CYCLOPHOSPHANUM [WHO-IP]
- 2H-1,3,2-OXAZAPHOSPHORIN-2-AMINE, N,N-BIS(2-CHLOROETHYL)TETRAHYDRO-, 2-OXIDE, MONOHYDRATE, (+/-)-
- 6055-19-2
- Ciclofosfamide
- 2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
- Cyclophosphamide (USP)
- HMS2234I13
- 8N3DW7272P
- DTXSID6024888
- Cyclophosphamide, European Pharmacopoeia (EP) Reference Standard
- Prestwick_137
- 2-(Bis(2-chloroethyl)amino)-1,3,2-oxazaphosphinane2-oxidehydrate
- Cyclophosphamide monohydrate, ISOPAC(R)
- NCGC00094636-04
- 2H-1,3,2-Oxazaphosphorine, tetrahydro-2-(bis(2-chloroethyl)amino)-, 2-oxide, monohydrate
- CCG-40013
- GLXC-10416
- DB-053644
- Cyclophosphamide hydrate (JP18)
- Cyclophosphamide hydrate?
- MDL： MFCD00149395
- Inchi： 1S/C7H15Cl2N2O2P.H2O/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14;/h1-7H2,(H,10,12);1H2
- InChI Key： PWOQRKCAHTVFLB-UHFFFAOYSA-N
- SMILES： ClCCN(CCCl)P1(NCCCO1)=O.O
- BRN： 8167897

Computed Properties

Exact Mass: 278.03500
Monoisotopic Mass: 278.035
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 5
Heavy Atom Count: 15
Rotatable Bond Count: 5
Complexity: 212
Covalently-Bonded Unit Count: 2
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 1
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Surface Charge: 0
Tautomer Count: 2
XLogP3: nothing
Topological Polar Surface Area: 42.6

Experimental Properties

Color/Form: White crystalline or crystalline powder
Melting Point: 49-51?°C (lit.)
Boiling Point: 110°C
Flash Point: Degrees Fahrenheit:235.4°F
Degrees Celsius:113°C
Solubility: H2O: 0.1?g/mL, clear, colorless
Water Partition Coefficient: 40 g/L
PSA: 60.61000
LogP: 2.14850
Merck: 2747
Sensitiveness: Sensitive to heat, light and air
Solubility: The solubility in water is 40g/l, slightly soluble in alcohol, benzene, ethylene glycol, carbon tetrachloride, dioxane, and almost insoluble in ether and acetone.

Cyclophosphamide hydrate Security Information

Symbol:
Prompt：dangerous
Signal Word：Danger
Hazard Statement： H301,H350
Warning Statement： P201,P301+P310,P308+P313
Hazardous Material transportation number：UN 3464 6.1/PG 3
WGK Germany：3
Hazard Category Code： 45-25
Safety Instruction： S53-S45-S37/39-S26
FLUKA BRAND F CODES：10
RTECS：RP6157750
Hazardous Material Identification：
HazardClass：6.1
PackingGroup：III
Storage Condition：2-8°C
Safety Term：6.1
Packing Group：II
Risk Phrases：R25; R36/37/38; R45; R46; R61
Packing Group：II
Hazard Level：6.1

Cyclophosphamide hydrate Customs Data

HS CODE：2924299090
Customs Data：

China Customs Code:
2934999090

Overview:

2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

Declaration elements:

Product Name, component content, use to

Summary:

2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Cyclophosphamide hydrate Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
MedChemExpress	HY-17420A-100mg	Cyclophosphamide hydrate	6055-19-2	99.97%	100mg	￥720	2025-04-16
S e l l e c k ZHONG GUO	S2057-50mg	Cyclophosphamide Monohydrate	6055-19-2	99.20%	50mg	￥785.09	2023-09-15
S e l l e c k ZHONG GUO	S2057-200mg	Cyclophosphamide Monohydrate	6055-19-2	99.20%	200mg	￥2375.1	2023-09-15
A FA AI SHA ， SAI MO FEI SHI ER KE JI QI XIA GONG SI	L11508-1g	Cyclophosphamide monohydrate, 97+%	6055-19-2	97+%	1g	￥393.00	2023-04-12
A FA AI SHA ， SAI MO FEI SHI ER KE JI QI XIA GONG SI	L11508-5g	Cyclophosphamide monohydrate, 97+%	6055-19-2	97+%	5g	￥1167.00	2023-04-12
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	BM2433-1g	Cyclophosphamide hydrate	6055-19-2		1g	￥330元	2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	BM2433-250mg	Cyclophosphamide hydrate	6055-19-2		250mg	￥165元	2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	BM2433-5g	Cyclophosphamide hydrate	6055-19-2		5g	￥1150元	2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	HC8239-1g	Cyclophosphamide hydrate	6055-19-2	≥98%	1g	￥125元	2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	HC8239-25g	Cyclophosphamide hydrate	6055-19-2	≥98%	25g	￥1920.00 元	2023-09-15

Cyclophosphamide hydrate Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:6055-19-2)環(huán)磷酰胺，一水

Order Number:LE1637635;LE12376

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:30

Price ($):discuss personally

Email:[email protected]

Suzhou Senfeida Chemical Co., Ltd

Gold Member

Audited Supplier

(CAS:6055-19-2)Cyclophosphamide monohydrate

Order Number:1637635

Stock Status:in Stock

Quantity:Company Customization

Purity:98%

Pricing Information Last Updated:Monday, 14 April 2025 21:49

Price ($):discuss personally

Email:[email protected]

Cyclophosphamide hydrate Spectrogram

LC-MS

1H NMR

300 MHz

DMSO

13C NMR

Cyclophosphamide hydrate Related Literature

1. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?

Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
2. An approach to biodegradable star polymeric architectures using disulfide coupling?

Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
3. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?

Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
4. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?

Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
5. An automatic determination of thoria in thoria-urania mixtures

Analyst, 1966,91, 208-210

Related Categories

Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Nitrogen mustard compounds

Additional information on Cyclophosphamide hydrate

Cyclophosphamide Hydrate (CAS No. 6055-19-2): A Pivotal Alkylating Agent in Modern Oncology and Immunotherapy

Cyclophosphamide hydrate, a crystalline compound with the CAS No. 6055-19-2, represents a cornerstone in the pharmacological arsenal against malignant diseases since its introduction in the mid-20th century. Structurally characterized by its phosphoramide backbone and oxazaphosphorine ring system, this cyclophosphamide derivative exhibits unique metabolic activation pathways that underpin its selective cytotoxicity toward rapidly proliferating cells. Recent advancements in drug delivery systems have further expanded its clinical utility, particularly through formulations optimizing bioavailability and minimizing off-target effects.

The mechanism of action of cyclophosphamide hydrate involves bioactivation via hepatic cytochrome P450 enzymes, generating phosphoramide mustard and acrolein metabolites that induce DNA cross-linking and apoptosis in neoplastic cells. A 2023 study published in Cancer Research revealed novel insights into its immunomodulatory effects, demonstrating how low-dose regimens can selectively deplete regulatory T-cells while preserving effector T-cell function—a discovery now informing combination strategies with checkpoint inhibitors. This dual role as both chemotherapeutic and immunotherapeutic agent positions it uniquely in modern oncology protocols.

In preclinical models, researchers have identified synergistic interactions between cyclophosphamide hydrate and targeted therapies such as PARP inhibitors. A landmark 2024 study from the MD Anderson Cancer Center demonstrated enhanced efficacy against triple-negative breast cancer xenografts when combining these agents with CDK4/6 inhibitors, suggesting potential for personalized dosing algorithms based on tumor biomarker profiles. Such findings align with precision medicine paradigms reshaping clinical practice.

Advances in pharmacokinetic understanding have led to innovative formulation approaches. Liposomal encapsulation technologies now enable sustained release profiles, reducing acute myelosuppression while maintaining antitumor efficacy—a critical breakthrough highlighted in a recent Nature Communications article evaluating pH-sensitive nanocarriers for localized delivery to solid tumors. These developments address longstanding challenges related to systemic toxicity without compromising therapeutic index.

In autoimmune disease management, emerging evidence supports cyclophosphamide's role beyond oncology. A Phase II trial reported in New England Journal of Medicine (NEJM) showed significant remission rates in severe lupus nephritis patients treated with pulsed low-dose regimens, corroborating its ability to modulate B-cell activity without excessive immunosuppression. This underscores the compound's evolving therapeutic spectrum across disciplines.

Mechanistic studies continue to uncover novel applications: a groundbreaking 2024 paper in Science Translational Medicine demonstrated that acrolein metabolites from cyclophosphamide hydrate induce mitochondrial dysfunction selectively in cancer-associated fibroblasts, suggesting potential roles in targeting tumor microenvironment components—a paradigm shift from traditional cell cycle-dependent cytotoxicity.

Ongoing research focuses on improving therapeutic windows through prodrug strategies and biomarker-driven protocols. A collaborative EU-funded initiative is investigating pharmacogenetic markers predicting response variability among lymphoma patients, while AI-driven predictive models aim to optimize dosing based on individual metabolic profiles—advances poised to transform this decades-old compound into a precision medicine tool for the 21st century.

6055-19-2 (Cyclophosphamide hydrate) Related Products

Recommended suppliers